Moreover, insight into stratifying tumor patients using biomarkers for selecting patients that may benefit from TGFβ targeting is urgently needed.24,25 In this review, we discuss recent clinical advancements and bottlenecks in anti-TGFβ cancer treatment, and provide perspectives of combined treatment to overcome chemo/targeted/radio-therapy resistance and increase the efficiency of immunotherapy responses in cancer patients. This evidence concerns the gene TGFB1 and neoplasm.